kras g12c inhibitor 4

KRas G12C inhibitor 4 is a compound that inhibits KRas G12C.

KRAS G12C inhibitor 47 is a potent inhibitor of KRAS G12C (IC50: 0.172 μM). KRAS G12C inhibitor 47 exhibits p-ERK inhibition in MIA PaCA-2 cells, A549 cells with IC50 values of 0.046 μM and 69.8 μM respectively. KRAS G12C inhibitor 47 showed investigational potential against pancreatic, colorectal and lung cancers.

KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.

KRAS G12C inhibitor 43 is a potent inhibitor of KRAS G12C and inhibits the migration and proliferation of H358 cells (IC50: 0.001-1 μM μM), A549 cells (IC50>1 μM) and HCC cells (IC50>1 μM).

KRAS G12C inhibitor 44 is a potent, orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 exhibits anti-proliferative effects in MIA PaCA-2 (IC50: 0.016 μM), H358 cells (IC50: 0.028 μM). inhibitor 44 has anti-tumour activity in vivo.

KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C, showing potential for the investigation of KRAS G12C-mediated cancers.

KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.

KRAS G12C inhibitor 45 is a potent KRAS G12C inhibitor .

KRAS G12C inhibitor 40, a potent suppressor of the KRAS G12C, targets the Ras family of intracellular signaling proteins crucial for growth and development. This compound holds significant potential for researching cancers mediated by KRAS G12C.

KRAS G12C Inhibitor 41 is a potent agent targeting the KRAS G12C mutation within the Ras family of proteins, which are crucial for intracellular signaling related to growth and development. This compound holds significant potential for advancing research in cancers mediated by KRAS G12C.

KRAS G12C Inhibitor 48 is a potent inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 value of 639.91 nM. Demonstrating antiproliferative activity, KRAS G12C Inhibitor 48 (0-50 µM) yields IC50 values of 0.796 µM, 6.33 µM, and 16.14 µM against H358, H23, and A549 cell lines, respectively.

AMG410 is a non-covalent, bimodal GDP (OFF) and GTP (ON)-binding pan-KRAS inhibitor with Kd (GDP) = 1 nM and Kd (GTP) = 22 nM, which enables circulation-independent blockade of KRAS. AMG410 is more than 100-fold selective for KRAS than HRAS and NRAS2, binds on the same variegated pocket as KRAS G12C inhibitors, and has high potency in KRAS G12D, G12V, G12C, G13D and other mutants, IC 50 = 1-4 nM. AMG140 regresses tumors and reduces phosphorylated ERK levels in colorectal, pancreatic and lung models of KRAS mutations.

K-Ras G12C-IN-4, is a potent Covalent Inhibitor of KRASG12C..

RAS RAS-RAF-IN-1 is a potent inhibitor of RAS and RAS-RAF, exhibiting a KD of 5.0 μμ-15 μμ for cyclophilin A (CYPA) binding affinity and demonstrating antitumor activity[1].

Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].